This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.


Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.



[Priority Issue 3]Contribute to Identifying Diseases at an Early Stage

 

Note: The article on this page is taken from Sustainability Report 2018.

Target and Key points in FY2017 Activities

Target for 2030

Reduce the physical burden through widespread and expanded use of medical diagnostic systems.

To maintain our health, it is important to detect diseases at an early stage even if there are no recognized symptoms, or take countermeasures for unpleasant symptoms before they have reached the level of disease. However, one in three Japanese people still do not take a regular health check* regardless of the seemingly wide understanding of the necessity for such proactive health checks. The Fujifilm Group contributes to the early detection and treatment of diseases through making easy-to-use self-health check systems widely available across society.

* The FY2014 National Health and Nutrition Survey by the Ministry of Health, Labour and Welfare reported that among people of ages 20 and above in Japan, 27.8% of males and 37.1% of females had not undergone a health check (general health check, health examination or complete medical examination) within the last year.

Outline of Activities in FY2017

[image]

  • Promoting the blood test service, CureSign, mainly for health insurance association members' family members who are not legally obligated to take regular health checks (FF)

* CureSign: A service in which a user collects a small sample of their own blood using a blood collection kit and sends the sample to the test center by post. Within a week or two, the blood test results will be sent back by post. Currently, available check items are stomach cancer, stomach ulcer, duodenal ulcer, and 14 items related to lifestyle diseases, including metabolic syndrome. The average number of annual users of the service as of FY2017 was 12,000.

Future Activities and Targets

  • Accelerate CureSign test service adoption by health insurance association, and as a part of the health check scheme prior to life insurance subscription. Assess market expansion overseas.
  • Continue business preparations in Thailand, as a part of the JETRO Project. The project is expected to be completed in September 2018.

Efforts to Improve the Medical Environment in Emerging Countries

Note: The article on this page is taken from Sustainability Report 2018.

Related Information

The Fujifilm Group examines CSR issues from both corporate and stakeholders' viewpoints and moves forward with its CSR activities by setting priority CSR targets and implementing specific measures.



Footer starts here.

Pages ends here.
Move to top of the page.